all-trans retinoic acid Clinical Trials

4 actively recruiting trials across 2 locations

Also known as: ATRA, Tretinoin, VESANOID, retinoic acid, tretinoin +1 more

Pipeline

Phase 2: 3Phase 1/2: 1

Top Sponsors

Stephen Bagley, MD, MSCE1
Gustave Roussy, Cancer Campus, Grand Paris1
Gabriel Tinoco1
Associazione Italiana Ematologia Oncologia Pediatrica1

Indications

Cancer4
IDH Mutation1
Acute Promyelocytic Leukemia1
Oligometastatic Disease1
Oligodendroglioma1

Other2 trials

Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer

Phase 1/2

Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

Phase 2

Columbus, Ohio1 trial

Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma

Ohio State University Comprehensive Cancer Center

Phase 2

Philadelphia, Pennsylvania1 trial

All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

University of Pennsylvania

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.